MetadataShow full item record
AbstractG protein-coupled receptors (GPCRs) self-associate as dimers or higher-order oligomers in living cells. The stability of associated GPCRs has not been extensively studied, but it is generally thought that these receptors move between the plasma membrane and intracellular compartments as intact dimers or oligomers. Here we show that b2-adrenergic receptors (b2ARs) that self-associate at the plasma membrane can dissociate during agonist-induced internalization. We use bioluminescence-resonance energy transfer (BRET) to monitor movement of Î²2ARs between subcellular compartments. BRET between b2ARs and plasma membrane markers decreases in response to agonist activation, while at the same time BRET between b2ARs and endosome markers increases. Energy transfer between b2ARs is decreased in a similar manner if either the donor- or acceptor-labeled receptor is mutated to impair agonist binding and internalization. These changes take place over the course of 30 minutes, persist after agonist is removed, and are sensitive to several inhibitors of arrestin- and clathrin-mediated endocytosis. The magnitude of the decrease in BRET between donor- and acceptor-labeled b2ARs suggests that at least half of the receptors that contribute to the BRET signal are physically segregated by internalization. These results are consistent with the possibility that b2ARs associate transiently with each other in the plasma membrane, or that b2AR dimers or oligomers are actively disrupted during internalization.
CitationPLoS One. 2011 Feb 22; 6(2):e17361
- Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET).
- Authors: Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, Bouvier M
- Issue date: 2000 Mar 28
- Differences in endosomal targeting of human (beta)1- and (beta)2-adrenergic receptors following clathrin-mediated endocytosis.
- Authors: Liang W, Curran PK, Hoang Q, Moreland RT, Fishman PH
- Issue date: 2004 Feb 15
- BRET evidence that β2 adrenergic receptors do not oligomerize in cells.
- Authors: Lan TH, Liu Q, Li C, Wu G, Steyaert J, Lambert NA
- Issue date: 2015 May 8
- Demonstration of a direct interaction between β2-adrenergic receptor and insulin receptor by BRET and bioinformatics.
- Authors: Mandić M, Drinovec L, Glisic S, Veljkovic N, Nøhr J, Vrecl M
- Issue date: 2014
- Beta2- and beta3-adrenoceptors activate glucose uptake in chick astrocytes by distinct mechanisms: a mechanism for memory enhancement?
- Authors: Hutchinson DS, Summers RJ, Gibbs ME
- Issue date: 2007 Nov
Showing items related by title, author, creator and subject.
Hydroxyurea induces fetal hemoglobin expression by activating cAMP signaling pathways in a cAMP- and cGMP-dependent mannerIkuta, Tohru; Gutsaeva, Diana R.; Parkerson, James B.; Yerigenahally, Shobha D; Head, C. Alvin; Department of Anesthesiology and Perioperative Medicine (American Society of Hematology, 2010-12)Here we show that hydroxyurea (HU) induces fetal hemoglobin (HbF) expression by activating the cAMP pathway through two independent mechanisms. Although HU increased both cAMP and cGMP levels in CD34+-derived erythroblasts, only the cAMP pathway was found to be activated. However, HU-induced HbF expression was affected by the activities of both adenylate cyclase (AC) and soluble guanylate cyclase (sGC). HU decreased the expression of cGMP-inhibitable phosphodiesterase (PDE) 3B in a sGC-dependent manner, resulting in activation of the cAMP pathway. Second, HU induced the expression of cyclooxygenase-1 (COX-1) and increased the production of prostaglandin E2 (PGE2), which resulted in activation of the cAMP signaling pathway through AC. HU therapy elevated plasma PGE2 levels in sickle cell patients. These results demonstrate that HU induces HbF expression by activating the cAMP pathway via dual signaling mechanisms.
Does the JNK/Jun Signaling Node Regulate Autophagy in Breast Cancer Cells?Joseph, Carol; Department of Cellular Biology and Anatomy; Schoenlein, Patricia V.; Department of Cellular Biology and Anatomy; Augusta University (2018-02-12)A common treatment for estrogen receptor positivebreast cancers is the use of selective estrogen receptor modulators such as Tamoxifen.1Unfortunately, 30-40% of patients experience relapse due tothe development ofantiestrogen resistance. Autophagy, a process that is typically seen in cells that are exposed to a variety of stresses, is critical to development of antiestrogen resistanceand may play a key role in metastatic progression.2,3 To further combat antiestrogen resistance, a potential target for breast cancers is JNK (c-Jun N-terminal kinase), a member of the mitogen-activated protein kinase (MAPK) family. The mechanismsby which JNK inhibition affects breast cancer cell growthare not fully characterized.Our hypothesis is that JNK is a key regulator of autophagy and the emergence of autophagy-dependent antiestrogen resistant breast cancer. Our aims are todetermine the effect of JNK inhibition on autophagy, cell number, and cell viability under conditions of antiestrogen treatment.By utilizingMCF-7breast cancercells andthe irreversible JNK-IN-8 inhibitor our current data provides strong evidence that JNK inhibition blocks autophagy. Data supporting a role for JNK in the regulation of antiestrogen-mediated autophagy have the potential to identify JNK as a molecular target for the improved treatment of breast cancer.
p65fl/fl/LysMCre Transgenic Mouse Model Shows Altered Nf-Kb Signaling In MacrophagesHoward, Shelby; Talkad, Aditi; Oza, Eesha; Department of Biological Sciences (2016-03)We have produced and begun characterizing a transgenic mouse model, p65fl/fl/LysMCre, that lacks canonical nuclear factor-kappaB (NF-kB) signaling (p65) in cells of the myeloid lineage, which includes macrophages. NF-kB pathway activity is very important in normal immune function, synaptic plasticity, and memory, and aberrant NF-kB activity is associated with autoimmune disease, and importantly, cancer. Macrophages can be present in very large numbers in a variety of cancers, and can lead to tumor progression through promotion of tumor inflammation, angiogenesis, invasion, and metastasis. This animal model will allow our group to pursue experiments involved in better understanding how stromal macrophages communicate with cancer cells through the NF-kB pathway, and how loss of canonical NF-kB signaling in cells of the myeloid lineage might weaken the tumor and make it more susceptible to standard treatments. Characterization of the model thus far reveals that p65 protein is indeed absent in macrophages derived from bone marrow monocytes, and that NF-kB signaling is altered when stimulated with lipopolysaccharide. We have just begun co-culture experiments with p65 deleted macrophages and glioma cells, and anticipate altered communication when compared to culture with control macrophages. Funding Source: Cancer Center Collaboration Grant